Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 14/20 | 0.61 |
| ▸ | CCNT1 | O60563 | 9/20 | 0.61 |
| ▸ | CCNB1 | P14635 | 9/20 | 0.61 |
| ▸ | CDK9 | P50750 | 9/20 | 0.61 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.56 |
| ▸ | MTOR | P42345 | 6/20 | 0.52 |
| ▸ | SMG1 | Q96Q15 | 5/20 | 0.52 |
| ▸ | CDK2 | P24941 | 7/20 | 0.51 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.51 |
| ▸ | CDK7 | P50613 | 3/20 | 0.51 |
| ▸ | CCNH | P51946 | 3/20 | 0.51 |
| ▸ | CCNA1 | P78396 | 3/20 | 0.51 |
| ▸ | GSK3B | P49841 | 2/20 | 0.49 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.47 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.47 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.47 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.47 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2542328 | 0.93 | CDK1 (0.59) | CDK1CCNT1CCNB1CDK9SLC2A1 | |
| SCHEMBL2546541 | 0.90 | CCNT1 (0.58) | CDK1CCNT1CCNB1CDK9CDK2 | |
| SCHEMBL2541106 | 0.85 | CDK1 (0.57) | CDK1CCNT1CCNB1CDK9SLC2A1 | |
| SCHEMBL2539352 | 0.85 | CDK1 (0.61) | CDK1CCNT1CCNB1CDK9SLC2A1 | |
| SCHEMBL2228483 | 0.84 | SLC2A1 (0.58) | CDK1CCNT1CCNB1CDK9SLC2A1 | |
| SCHEMBL12611335 | 0.84 | CDK1 (0.69) | CDK1CCNT1CCNB1CDK9SLC2A1 | |
| SCHEMBL2545739 | 0.83 | CCNT1 (0.57) | CDK1CCNT1CCNB1CDK9CDK2 | |
| SCHEMBL2540573 | 0.81 | CDK1 (0.56) | CDK1CCNT1CCNB1CDK9SLC2A1 | |
| SCHEMBL2540708 | 0.80 | CDK1 (0.56) | CDK1CCNT1CCNB1CDK9SLC2A1 | |
| SCHEMBL2545044 | 0.80 | CDK1 (0.60) | CDK1CCNT1CCNB1CDK9SLC2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140303163-A1 | USE OF KINASE INHIBITORS IN PREVENTING AND TREATING INFLAMMATORY DISORDER | LUO YING (CN) | 2014-10-09 | — | — | US | claimed |
| WO-2012126181-A1 | USE OF KINASE INHIBITORS IN PREVENTING AND TREATING INFLAMMATORY DISORDER | LUO YING (CN) | 2012-09-27 | — | — | WO | claimed |
| US-20110263541-A1 | KINASE INHIBITORS AND THEIR USE AS PHARMACEUTICAL AGENTS | SHANGHAI GENOMICS, INC (CN) | 2011-10-27 | — | — | US | claimed |
| US-20140303163-A1 | USE OF KINASE INHIBITORS IN PREVENTING AND TREATING INFLAMMATORY DISORDER | LUO YING (CN) | 2014-10-09 | — | — | US | disclosed |
| US-8309550-B2 | Kinase inhibitors and their use as pharmaceutical agents | SHANGHAI GENOMICS, INC. (CN) | 2012-11-13 | — | — | US | disclosed |
| US-8309550-B2 | Kinase inhibitors and their use as pharmaceutical agents | SHANGHAI GENOMICS, INC. (CN) | 2012-11-13 | — | — | US | disclosed |
| US-8309550-B2 | Kinase inhibitors and their use as pharmaceutical agents | SHANGHAI GENOMICS, INC. (CN) | 2012-11-13 | — | — | US | disclosed |
| US-20110263541-A1 | KINASE INHIBITORS AND THEIR USE AS PHARMACEUTICAL AGENTS | SHANGHAI GENOMICS, INC (CN) | 2011-10-27 | — | — | US | disclosed |
| US-20110263541-A1 | KINASE INHIBITORS AND THEIR USE AS PHARMACEUTICAL AGENTS | SHANGHAI GENOMICS, INC (CN) | 2011-10-27 | — | — | US | disclosed |
| US-20110263541-A1 | KINASE INHIBITORS AND THEIR USE AS PHARMACEUTICAL AGENTS | SHANGHAI GENOMICS, INC (CN) | 2011-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263541-A1 | KINASE INHIBITORS AND THEIR USE AS PHARMACEUTICAL AGENTS | MAP3K20, MAP3K1, MAP3K2 | CDK1 129/4885CCNT1 1213/4885CCNB1 1308/4885 |
| US-20140303163-A1 | USE OF KINASE INHIBITORS IN PREVENTING AND TREATING INFLAMMATORY DISORDER | NFKBIA, IRAK1, IRAK3 | CDK1 465/4885CCNT1 3334/4885CCNB1 2741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.